Nona Biosciences: Announces Global License and Option Agreement With AstraZeneca for Monoclonal Antibody to Be Developed Into Novel Tumor Targeted Therapies
Nona Biosciences: Announces Global License and Option Agreement With AstraZeneca for Monoclonal Antibody to Be Developed Into Novel Tumor Targeted Therapies
Nona Biosciences:宣布与阿斯利康签订全球许可和期权协议,将单克隆抗体开发成新的肿瘤靶向疗法
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册